# Erich Schlick

> Erich Schlick is a Series A investor at Wellington Partners backing Medical and Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Wellington Partners](https://shizune.co/investors/profile/wellington-partners)
- Location: Munich, Germany
- Total investments: 9
- Last investment: Mar 2020
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://de.linkedin.com/pub/erich-schlick/1/711/429

Erich Schlick is a Series A investor at Wellington Partners in Munich focused on Medical and Health Care. Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when Erich initiated the development of Humira, the first fully human therapeutic monoclonal antibody. Erich joined Wellington as an Investment Partner for Life Sciences in October 2005. Beforethis, Erich served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, Erich obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, Erich established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich is a qualified medical doctor and a professor of immunopharmacology at the University of Heidelberg.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 22% |
| Health Care | 1 | 11% |
| Therapeutics | 1 | 11% |
| Biotechnology | 1 | 11% |
| Medical Device | 1 | 11% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 22% |
| Series C | 2 | 22% |
| Series B | 1 | 11% |
| Series D | 1 | 11% |
| Series E | 1 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 11% |
| Switzerland | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $104M | Post-IPO Equity | Mar 17, 2020 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $58M | Series E | Oct 04, 2017 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $24.1M | Series D | Jul 16, 2014 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $13.2M | Series D | Oct 15, 2013 |  |
| SENSIMED | Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland. |  | Series C | Oct 09, 2012 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $59.2M | Series C | Sep 21, 2010 |  |
| SENSIMED | Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland. | $9.3M | Series A | Dec 17, 2007 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $43.9M | Series B | Feb 08, 2007 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $8.6M | Series A | Feb 11, 2004 |  |

9 of 9 investments shown.

## Co-investors
- [dievini Hopp Biotech Holding](https://shizune.co/investors/profile/dievini-hopp-biotech-holding) — VC Fund, 6 deals together
- [VINCI CAPITAL](https://shizune.co/investors/profile/vinci-capital) — VC Fund, 3 deals together
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 2 deals together
- [AT Impf](https://shizune.co/investors/profile/at-impf) — VC Fund, 2 deals together
- [Agate Medical Investments](https://shizune.co/investors/profile/agate-medical-investments) — VC Fund, 1 deal together
- [Amgen Inc.](https://shizune.co/investors/profile/amgen) — VC Fund, 1 deal together

## About Wellington Partners

VC Fund · Munich, Germany

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

5 contacts available at Wellington Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Erich Schlick | General Partner | https://shizune.co/investors/profile/erich-schlick |
| Rolf Christof Dienst | General Partner and Founder Emeritus | https://shizune.co/investors/profile/rolf-christof-dienst |
| Anja Weibel | Finance Manager | https://shizune.co/investors/profile/anja-weibel |
| Frank Boehnke | General Partner | https://shizune.co/investors/profile/frank-boehnke |
| Harald Keller | Partner | https://shizune.co/investors/profile/harald-keller |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Erich Schlick invest in?

Erich Schlick invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 9 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Erich Schlick last invest?

The most recent investment recorded for Erich Schlick closed in Mar 2020. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co